Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Amgen is going to hunt down the last remnants of ALL
Company: Amgen (AMGN)
Therapy: Blinatumomab
Disease: Acute lymphoblastic leukemia
News: AMGN announced that the FDA has approved its supplemental application for blinatumomab for use in patients with acute lymphoblastic leukemia who have so-called "minimal residual